A Phase 1/2 Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs CV 301 (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MAGNI-lung-01
- Sponsors Bavarian Nordic
- 29 Dec 2016 Status changed from not yet recruiting to recruiting, according to Bavarian Nordic media release.
- 23 Jul 2016 Status changed from planning to not yet recruiting.
- 06 Nov 2015 New trial record